Targeting senescent cells in translational medicine.
View / Open Files
Publication Date
2019-11-19ISSN
1757-4676
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Paez-Ribes, M., González-Gualda, E., Doherty, G. J., & Muñoz-Espín, D. (2019). Targeting senescent cells in translational medicine.. https://doi.org/10.15252/emmm.201810234
Description
Funder: La Caixa" Foundation
Abstract
Organismal ageing is a complex process driving progressive impairment of functionality and regenerative potential of tissues. Cellular senescence is a state of stable cell cycle arrest occurring in response to damage and stress and is considered a hallmark of ageing. Senescent cells accumulate in multiple organs during ageing, contribute to tissue dysfunction and give rise to pathological manifestations. Senescence is therefore a defining feature of a variety of human age-related disorders, including cancer, and targeted elimination of these cells has recently emerged as a promising therapeutic approach to ameliorate tissue damage and promote repair and regeneration. In addition, in vivo identification of senescent cells has significant potential for early diagnosis of multiple pathologies. Here, we review existing senolytics, small molecules and drug delivery tools used in preclinical therapeutic strategies involving cellular senescence, as well as probes to trace senescent cells. We also review the clinical research landscape in senescence and discuss how identifying and targeting cellular senescence might positively affect pathological and ageing processes.
Keywords
Cellular senescence, SASP, Age-related Disorders, Senolytic Drugs, Senoprobes
Sponsorship
Cancer Research UK (C62187/A26989)
Royal Society (RG160806)
University of Cambridge (C9685/125117)
UK Research and Innovation|Medical Research Council (MRC) (MR/R000530/1)
Identifiers
31746100, PMC6895604
External DOI: https://doi.org/10.15252/emmm.201810234
This record's URL: https://www.repository.cam.ac.uk/handle/1810/300243